Temel Halide E, Akyuz Fahrettin
Department of Biochemistry, Faculty of Pharmacy, University of Anadolu, Eskisehir, Turkey.
J Enzyme Inhib Med Chem. 2007 Apr;22(2):213-7. doi: 10.1080/14756360601051324.
Diabetes mellitus induces a decrease in sodium potassium-adenosine triphosphatase (Na+/K(+)-ATPase) activity in several tissues in the rat and red blood cells (RBC) and nervous tissue in human patients. This decrease in Na+/K(+)-ATPase activity is thought to play a role in the development of long-term complications of the disease. Angiotensin enzyme inhibitors (ACEi) and angiotensin-II receptor antagonists (ARBs) reduce proteinuria and retard the progression of renal failure in patients with IDDM and diabetic rats. We investigated the effects of captopril and losartan, which are used in the treatment of diabetic nephropathy, on Na+/K(+)-ATPase activity. Captopril had an inhibitory effect on red cell plasma membrane Na+/K+ ATPase activity, but losartan did not. Our study draws attention to the inhibitory effect of captopril on Na+/K+ ATPase activity. Micro and macro vascular complications are preceeding mortality and morbidity causes in diabetes mellitus. There is a strong relationship between the decrease in Na+/K+ ATPase activity and hypertension. The non-sulphydryl containing ACEi and ARBs must be the choice of treatment in hypertensive diabetic patients and diabetic nephropathy.
糖尿病会导致大鼠多个组织以及人类患者红细胞（RBC）和神经组织中的钠钾 - 三磷酸腺苷酶（Na⁺/K⁺ - ATP酶）活性降低。这种Na⁺/K⁺ - ATP酶活性的降低被认为在该疾病长期并发症的发展中起作用。血管紧张素酶抑制剂（ACEi）和血管紧张素II受体拮抗剂（ARBs）可减少蛋白尿，并延缓胰岛素依赖型糖尿病患者和糖尿病大鼠肾衰竭的进展。我们研究了用于治疗糖尿病肾病的卡托普利和氯沙坦对Na⁺/K⁺ - ATP酶活性的影响。卡托普利对红细胞质膜Na⁺/K⁺ - ATP酶活性有抑制作用，但氯沙坦没有。我们的研究提请注意卡托普利对Na⁺/K⁺ - ATP酶活性的抑制作用。微血管和大血管并发症是糖尿病患者死亡和发病的主要原因。Na⁺/K⁺ - ATP酶活性降低与高血压之间存在密切关系。不含巯基的ACEi和ARBs必定是高血压糖尿病患者和糖尿病肾病治疗的选择。
